Sernova Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Cynthia Pussinen

Algemeen directeur

CA$2.6m

Totale compensatie

Percentage CEO-salaris	3.6%
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Cynthia Pussinen's beloning veranderd ten opzichte van Sernova's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jul 31 2024	n/a	n/a	-CA$39m
Apr 30 2024	n/a	n/a	-CA$41m
Jan 31 2024	n/a	n/a	-CA$41m
Oct 31 2023	CA$3m	CA$92k	-CA$39m

Compensatie versus markt: De totale vergoeding ($USD 1.91M ) Cynthia } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 503.65K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Cynthia te vergelijken met de prestaties van het bedrijf.

CEO

Cynthia Pussinen

1.1yrs

Tenure

CA$2,574,600

Compensatie

Ms. Cynthia Pussinen is Chief Executive Officer & Director at Sernova Corporation from September 2023. She served as an Executive Vice President of Technical Operations and Supply Chain at Actinium Pharmac...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Cynthia Pussinen	CEO & Director	1.1yrs	CA$2.57m	geen gegevens
James Parsons	CFO & Director	no data	CA$183.27k	0.12% € 64.1k
Modestus Obochi	Chief Business Officer	1.1yrs	CA$996.01k	0.015% € 8.3k
Frank Shannon	Vice President of Clinical Development & Regulatory Affairs	3.2yrs	CA$463.26k	geen gegevens
Jonathan M. Rigby	Executive Chairman	less than a year	geen gegevens	geen gegevens
Douglas Maret	Chief Science Officer	no data	geen gegevens	geen gegevens
David Burke	Vice President of Investor Relations	less than a year	geen gegevens	geen gegevens
Marylyn Rigby	Chief Communications Officer	no data	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van PSH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Cynthia Pussinen	CEO & Director	1.1yrs	CA$2.57m	geen gegevens
James Parsons	CFO & Director	12.5yrs	CA$183.27k	0.12% € 64.1k
Jonathan M. Rigby	Executive Chairman	less than a year	geen gegevens	geen gegevens
Norman C. Wong	Member of Scientific Advisory Board	18.3yrs	geen gegevens	geen gegevens
Jannette Dufour	Member of Scientific Advisory Board	18.2yrs	geen gegevens	geen gegevens
George King	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Clive Patience	Member of Scientific Advisory Board	17.8yrs	geen gegevens	geen gegevens
Steven Paraskevas	Member of Scientific Advisory Board	13.8yrs	geen gegevens	geen gegevens
David Lillicrap	Member of Scientific Advisory Board	5.8yrs	geen gegevens	geen gegevens
Anke Schulte	Member of Global Advisory Board	4.3yrs	geen gegevens	geen gegevens
Stephen Sangha	Independent Director	1.5yrs	CA$158.36k	4.01% € 2.2m
Sam Wiseman	Member of Scientific Advisory Board	3.5yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PSH wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Sernova Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Independent Director recently sold €149k worth of stock

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Recent updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Independent Director recently sold €149k worth of stock

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New major risk - Share price stability

New minor risk - Market cap size

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

New minor risk - Share price stability

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought €162k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought €51k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd